Trial · NCT02418845
Results by group30
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 30
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Clinical Outcome Responder Rate | SYM-1219 | Clinical Outcome Responder | 57 | Participants | |
| Clinical Outcome Responder Rate | Placebo | Clinical Outcome Responder | 11 | Participants | |
| Clinical Outcome Responder Rate | SYM-1219 | Non-Responder | 50 | Participants | |
| Clinical Outcome Responder Rate | Placebo | Non-Responder | 46 | Participants | |
| Clinical Outcome Responder Rate (Interim Visit Only) | SYM-1219 | Clinical Outcome Responder | 62 | Participants | |
| Clinical Outcome Responder Rate (Interim Visit Only) | Placebo | Clinical Outcome Responder | 14 | Participants | |
| Clinical Outcome Responder Rate (Interim Visit Only) | SYM-1219 | Non-Responder | 45 | Participants | |
| Clinical Outcome Responder Rate (Interim Visit Only) | Placebo | Non-Responder | 43 | Participants | |
| Gram Stain Slide Nugent Score | SYM-1219 | Study days 7-14 (interim) / Nugent Score 0-3 | 49 | Participants | |
| Gram Stain Slide Nugent Score | Placebo | Study days 7-14 (interim) / Nugent Score 0-3 | 2 | Participants | |
| Gram Stain Slide Nugent Score | SYM-1219 | Study days 7-14 (interim) / Nugent Score 4 or greater | 58 | Participants | |
| Gram Stain Slide Nugent Score | Placebo | Study days 7-14 (interim) / Nugent Score 4 or greater | 55 | Participants | |
| Gram Stain Slide Nugent Score | SYM-1219 | Study days 21-30 (EOS) / Nugent Score 0-3 | 47 | Participants | |
| Gram Stain Slide Nugent Score | Placebo | Study days 21-30 (EOS) / Nugent Score 0-3 | 3 | Participants | |
| Gram Stain Slide Nugent Score | SYM-1219 | Study days 21-30 (EOS) / Nugent Score 4 or greater | 60 | Participants | |
| Gram Stain Slide Nugent Score | Placebo | Study days 21-30 (EOS) / Nugent Score 4 or greater | 54 | Participants | |
| Therapeutic Outcome Responder Rate | SYM-1219 | Study days 7-14 (interim) / Therapeutic Outcome Responder | 37 | Participants | |
| Therapeutic Outcome Responder Rate | Placebo | Study days 7-14 (interim) / Therapeutic Outcome Responder | 2 | Participants | |
| Therapeutic Outcome Responder Rate | SYM-1219 | Study days 7-14 (interim) / Non-Responder | 70 | Participants | |
| Therapeutic Outcome Responder Rate | Placebo | Study days 7-14 (interim) / Non-Responder | 55 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02418845/results